1Nozawa R, Suzuki J, Takahashi A, et al. Clinicopathological features and the prognosis of IgA nephropathy in Japanese children on long-term observation. Clin Nephrol, 2005, 64:171 - 179.
2Ruggenenti P, Perna A, Gherardi G, et al. Reneprotective properties of ACE-inhibition in non-diabetic nephropathies with non proteinuria. Lancet, 1999, 354:359-364.
7Dillon JJ. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for lgA nephropathy. Semin Nephrol, 2004, 24:218-224.
8Syrjanen J, Huang XH, Mustonen J, et al. Angiotensinconverting enzyme insertion/deletion polemorphism and prognosis of IgA nephrophthy. Nephron, 2000, 86:115-121.
3Wolf G,Butzmann U,Wenzel UO.The renin-angiotensin system and progression of renal disease:from hemodynamics to cell biology.Nephrol Physiol,2003,93:3-13.
4Nishiyama A,Seth DM,Navar LG.Renal interstitial fluid concentrations of angiotensins Ⅰ and Ⅱ in anesthetized rats.Hypertension,2002,39:129-134.
5Van Kats JP,Schalekamp MA,Verdouw PD,et al.Intrarenal angiotensin Ⅱ:interstitial and cellular levels and site of production.Kidney Int,2001,60:2311-2317.
6Peti-Peterdi J,Warnock DG,Bell PD.Angiotensin Ⅱdirectly stimulates EnaC activity in the collecting duct via AT1 receptors.J Am Soc Nephrol,2002,13:1131-1135.
7Richard V,Hurel-Merle S,Scalbert E,et al.Functional evidence for a role of vascular chymase in the production of angiotensin Ⅱ in isolated human arteries.Circulation,2001,104:750-752.
8Husain A,Li M,Graham RM.Do studies with ACE N-and C-domain-selective inhibitors provide evidence for a nonACE,non-chymase angiotensin H-forming pathway? Cir Res,2003,93:91-93.
9Durvasula RV,Petermann AT,Hiromura K,et al.Activation of a local tissue angiotensin system in podocytes by mechanical strain.Kidney Int,2004,65:30-39.
10Kohlstedt K,Brandes RP,Muller-Esterlw,et al.Angiotensin-converting enzyme is involved in outside-in signaling in endothelial cells.Cir Res,2004,94:60-67.
